Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoViricides has entered into an agreement with the University of Pittsburgh for the testing of its nanoviricides drug candidates in standard animal models of ocular virus infections.
Subscribe to our email newsletter
The research will be performed in the Charles T. Campbell Ophthalmic Microbiology Laboratory by Dr. Eric Romanowski, Research Director. Dr. Romanowski has extensive experience in ocular virus infections and anti-viral agents discovery.
These animal studies will evaluate the efficacy and potency of the Company’s nanoviricides anti-viral agents in ocular viral infections. The goal of these studies is to help select clinical drug development candidates for treatment of ocular herpes keratitis in humans.
NanoViricides CEO Eugene Seymour said: "We are very pleased to have the Campbell Laboratory join our efforts in developing a drug against Herpes Keratitis.
"This is a renowned lab in the field of ocular infections with substantial experience in antiviral drugs development. We plan to perform IND-enabling efficacy studies of our anti-viral agents at the Campbell Labs."
The Charles T. Campbell Ophthalmic Microbiology Laboratory is part of the University of Pittsburgh Medical Center’s Eye Center (UPMC Eye Center). The UPMC Eye Center in the Department of Ophthalmology of the University of Pittsburgh School of Medicine has one of the top basic and clinical research programs in the country.
UPMC Eye Center’s research focuses on infectious disease, ocular immunology, molecular genetics and molecular biology of retinal disease, glaucoma and advanced diagnostic imaging technology development.